Abstract
Background Acute renal transplant rejection isone of the most important complications of thismedical procedure. This study compares the first year rate of rejection in patients that receiveddaclizumab or basiliximab as initial immunosuppression induction drug. Methods It ́s an observational, retrospectivecohort study and includes patients between January 2000 and December 2008. The source ofpatients was the Nephrology Service of Calderón Guardia Hospital. The target population was allthe patients with renal transplant whom receivedbasiliximab or daclizumab as initial immunosuppression induction drug. Results Acute renal transplant rejection wasmore often seen in the group of patients thatreceived basiliximab, compared with the daclizumab group. Discussion The acute renal rejection rate in thefirst year post surgery in Calderón Guardia Hospital, showed statistically significant differencesbetween the daclizumab group and the basiliximab group. In the basiliximab group there wheremore patients with acute rejection.